- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Ramaprasad Srinivasan, MD, PhD | Authors
Ramaprasad Srinivasan, MD, PhD, on the Results of MK-6482 in VHL Associated Disease
December 23, 2020
Study results indicated that MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated clear cell renal cell carcinoma, pancreatic lesions, and hemangioblastomas by targeting the underlying pathophysiology of the disease.
Ramaprasad Srinivasan, MD, PhD, on the Design of the Study of MK-6482 in VHL-Associated Disease
December 14, 2020
Data presented at SUO indicated that MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated clear cell renal cell carcinoma, pancreatic lesions, and hemangioblastomas by targeting the underlying pathophysiology of the disease.
Ramaprasad Srinivasan, MD, PhD, on Upcoming Research for Kidney Cancer
December 06, 2020
The kidney cancer expert from the National Cancer Institute spoke about what ongoing research in the field of kidney cancer is most encouraging and where research should continue to be focused.